Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results

Detalhes bibliográficos
Autor(a) principal: Busch, Catharina
Data de Publicação: 2019
Outros Autores: Fraser-Bell, Samantha, Iglicki, Matias, Lupidi, Marco, Couturier, Aude, Chaikitmongkol, Voraporn, Giancipoli, Ermete, Rodríguez-Valdés, Patricio J., Gabrielle, Pierre-Henri, Laíns, Inês, Santos, Ana Rita, Cebeci, Zafer, Amphornphruet, Atchara, Degenhardt, Valentin, Unterlauft, Jan-Darius, Cagini, Carlo, Mané-Tauty, Valérie, Ricci, D'Amico Giuseppe, Hindi, Isaac, Agrawal, Kushal, Chhablani, Jay, Loewenstein, Anat, Zur, Dinah, Regak, Matus
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.22/16930
Resumo: The beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.
id RCAP_f7a620d25b178178d710218f8551b8af
oai_identifier_str oai:recipp.ipp.pt:10400.22/16930
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year resultsRefractory diabetic macular edemaAnti-VEGF therapyDexamethasone implantIntravitreal therapyLong- term outcomeThe beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.SpringerRepositório Científico do Instituto Politécnico do PortoBusch, CatharinaFraser-Bell, SamanthaIglicki, MatiasLupidi, MarcoCouturier, AudeChaikitmongkol, VorapornGiancipoli, ErmeteRodríguez-Valdés, Patricio J.Gabrielle, Pierre-HenriLaíns, InêsSantos, Ana RitaCebeci, ZaferAmphornphruet, AtcharaDegenhardt, ValentinUnterlauft, Jan-DariusCagini, CarloMané-Tauty, ValérieRicci, D'Amico GiuseppeHindi, IsaacAgrawal, KushalChhablani, JayLoewenstein, AnatZur, DinahRegak, Matus2021-02-09T10:17:20Z2019-09-212019-09-21T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/16930engBusch, C., Fraser-Bell, S., Iglicki, M. et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56, 1341–1350 (2019). https://doi.org/10.1007/s00592-019-01416-410.1007/s00592-019-01416-4metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-13T13:05:13Zoai:recipp.ipp.pt:10400.22/16930Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:36:34.632238Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
title Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
spellingShingle Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
Busch, Catharina
Refractory diabetic macular edema
Anti-VEGF therapy
Dexamethasone implant
Intravitreal therapy
Long- term outcome
title_short Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
title_full Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
title_fullStr Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
title_full_unstemmed Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
title_sort Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
author Busch, Catharina
author_facet Busch, Catharina
Fraser-Bell, Samantha
Iglicki, Matias
Lupidi, Marco
Couturier, Aude
Chaikitmongkol, Voraporn
Giancipoli, Ermete
Rodríguez-Valdés, Patricio J.
Gabrielle, Pierre-Henri
Laíns, Inês
Santos, Ana Rita
Cebeci, Zafer
Amphornphruet, Atchara
Degenhardt, Valentin
Unterlauft, Jan-Darius
Cagini, Carlo
Mané-Tauty, Valérie
Ricci, D'Amico Giuseppe
Hindi, Isaac
Agrawal, Kushal
Chhablani, Jay
Loewenstein, Anat
Zur, Dinah
Regak, Matus
author_role author
author2 Fraser-Bell, Samantha
Iglicki, Matias
Lupidi, Marco
Couturier, Aude
Chaikitmongkol, Voraporn
Giancipoli, Ermete
Rodríguez-Valdés, Patricio J.
Gabrielle, Pierre-Henri
Laíns, Inês
Santos, Ana Rita
Cebeci, Zafer
Amphornphruet, Atchara
Degenhardt, Valentin
Unterlauft, Jan-Darius
Cagini, Carlo
Mané-Tauty, Valérie
Ricci, D'Amico Giuseppe
Hindi, Isaac
Agrawal, Kushal
Chhablani, Jay
Loewenstein, Anat
Zur, Dinah
Regak, Matus
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Politécnico do Porto
dc.contributor.author.fl_str_mv Busch, Catharina
Fraser-Bell, Samantha
Iglicki, Matias
Lupidi, Marco
Couturier, Aude
Chaikitmongkol, Voraporn
Giancipoli, Ermete
Rodríguez-Valdés, Patricio J.
Gabrielle, Pierre-Henri
Laíns, Inês
Santos, Ana Rita
Cebeci, Zafer
Amphornphruet, Atchara
Degenhardt, Valentin
Unterlauft, Jan-Darius
Cagini, Carlo
Mané-Tauty, Valérie
Ricci, D'Amico Giuseppe
Hindi, Isaac
Agrawal, Kushal
Chhablani, Jay
Loewenstein, Anat
Zur, Dinah
Regak, Matus
dc.subject.por.fl_str_mv Refractory diabetic macular edema
Anti-VEGF therapy
Dexamethasone implant
Intravitreal therapy
Long- term outcome
topic Refractory diabetic macular edema
Anti-VEGF therapy
Dexamethasone implant
Intravitreal therapy
Long- term outcome
description The beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was main- tained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.
publishDate 2019
dc.date.none.fl_str_mv 2019-09-21
2019-09-21T00:00:00Z
2021-02-09T10:17:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.22/16930
url http://hdl.handle.net/10400.22/16930
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Busch, C., Fraser-Bell, S., Iglicki, M. et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol 56, 1341–1350 (2019). https://doi.org/10.1007/s00592-019-01416-4
10.1007/s00592-019-01416-4
dc.rights.driver.fl_str_mv metadata only access
info:eu-repo/semantics/openAccess
rights_invalid_str_mv metadata only access
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131456649297920

Registros relacionados